We entered 26 patients with newly diagnosed acute promyelocytic leukemia (APL) in a pilot study of all-transretinoic acid (ATRA) followed by intensive chemotherapy. Median age was 46 (range 25 t o 63). No patient presented with leukocytes >10 x 109/L or had the microgranular APL variant. Cytogenetic analysis (25 patients) found a t(15;17) in 24 cases. Patients were scheduled t o receive ATRA (45 mg/m2/d) until complete remission, followed by an intensive daunorubicin (DNR) + Ara C course ("4 + 7" course), then three "2 + 5" DNR + Ara C courses and maintenance chemotherapy. However, the "4 + 7" course was administered in emergency if hyperleukocytosis rapidly developed t o prevent leukostasis. Twenty-five patients (96%) achieved CR, 14 with ATRA alone and 11 after the addition of the "4 + 7" course on day 2 t o 30 of treatment, because leukocytes rapidly increased (9 cases), because of resistance t o ATRA (1 case), and development of organomegaly (1 case). The remaining patient died on day 6, from CNS bleeding. Apart from hyperleukocytosis, side effects were usually moderate. In the 11 patients who could be studied in vitro, a very good correlation was found between in vivo and vitro differentiation and proliferation of APL blasts with ATRA. Three patients were allografted after the "4 + 7" course. Four patients did not receive this course but received the subsequent "2 + NTENSIVE CHEMOTHERAPY, combining an anthra-I cycline (or its derivatives) and cytosine arabinoside (Ara C) yields complete remission (CR) in 70% to 75% of the cases of acute promyelocytic leukemia (APL) and 35% to 40% of the patients achieving CR have prolonged remission with adequate consolidation However, 25% to 30% of the APL patients fail to achieve CR, mainly because of death caused by bleeding during treatment, or sepsis during the chemotherapy induced period of aplasia, rather than true leukemic resistance, which is rare in APL.1-8 Bleeding results from the release of procoagulants from the APL cells that trigger disseminated intravascular coagulation (DIC) but also fibrinolysis and proteolysis?
5 courses and maintenance. The remaining patients followed the scheduled protocol. Three patients relapsed after 8,11, and 15 months (including one allografted patient). Two patients died in CR, after 6 and 17 months. The other 20 patients remained in CR after 18+ t o 34+ months (median 21). Actuarial disease free interval (DFI) and event free survival (EFS) were 87% and 77%. respectively, after 18 months.
These results were compared t o those obtained in our previous APL 84 trial with chemotherapy alone in newly diagnosed APL (after excluding patients included in this trial who presented with hyperleukocytosis). In APL 84 trial, the CR rate was 76%, the actuarial DFI and EFS were 59% and 48% after 18 months, respectively. Differences with the pilot study of ATRA followed by chemotherapy were significant for DFI (P = .02), EFS (P = .006), but not for CR rate (P = .08).
Although this is a historical comparison, these results suggest that ATRA followed by chemotherapy may prove superior t o chemotherapy alone in newly diagnosed APL, by slightly increasing the CR rate, but perhaps more importantly by reducing the relapse rate. This question is now being addressed t o in a multicenter trial randomizing between the two therapeutic approaches in newly diagnosed APL. in APL.l0 Our group and other groups have shown that ATRA was capable of inducing a high CR rate in APL, both in newly diagn0~edll-l~ and first relapse patients. 15 Response to ATRA was associated to rapid improvement of the hemostatic disorder and occurred in the absence of any phase of aplasia, suggesting that treatment with ATRA could reduce the two main causes of failure to achieve CR with chemotherapy in APL. However, in some patients, treatment with ATRA was associated to rapidly developing hyperleukocytosis, leading to life threatening leukostasis, and a "retinoic acid syndrom" unless rapid reduction in leukocyte counts was obtained.16-ls In addition, most of the patients who achieved CR with ATRA and were maintained on ATRA alone or relatively mild chemotherapy rapidly relapsed.l*-15 These findings prompted us to start a pilot phase combining ATRA and intensive chemotherapy in newly diagnosed AF' L. Intensive chemotherapy was administered either after CR had been obtained with ATRA alone, to further reduce the leukemic burden, or was rapidly added to ATRA during the induction phase in patients with rapidly developing hyperleukocytosis, to prevent leukostasis.
PATIENTS AND METHODS
Between November 1989 and February 1991, 26 patients with newly diagnosed APL from 11 French hematologic centers entered a pilot study of treatment with ATRA followed by intensive chemotherapy. Diagnosis of APL was based on French-American-British (FAB) riter ria.'^,^^ Patients were included in this pilot trial if they had leukocyte counts below 10 x 109/L, had no contraindication to intensive chemotherapy, and had given their informed consent.
Cytogenetic analysis was performed at diagnosis in 25 patients. A study of in vitro differentiating and proliferating activity of ATRA on abnormal promyelocytes was performed in 11 patients, as previously described.1° Briefly, in vitro differentiation was assessed by morphologic criteria and the nitroblue tetrazolium (NBT) reduction test, and proliferation by the comparative increase of the viable cell count (ATRA versus control at day 3 of culture). The hemostatic disorder (DIC and/or fibrinolysis) was considered significant when at least two of the following criteria were present:
fibrinogen < 1.8 g/L; prothrombin time (PT) or factor V <60%; fibrin split product (FSP) >40 kL/mL, in the absence of liver disease. In this definition, no attempt at trying to distinguish DIC or fibrinolysis was made. Treatment consisted of ATRA 45 mg/m2/d orally until CR achievement. As soon as CR was obtained, an intensive consolidation course, combining daunorubicin (DNR) 60 mg/m2/d days 1 to 4 (bolus intravenous [IV] injection) and Ara C 100 mg/m2/d days 1 to 7 (continuous infusion) was scheduled. This "4 + 7" course was administered in emergency (ATRA being continued at the same dosage) if, under ATRA, leukocytes increased above 6 X 109/L by day 5 of the treatment, or above 10 x 109/L by day 10, or above 15 x 109/L by day 15 because, in our previous experience, patients with a rapid increase in leukocyte count beyond these thresholds rapidly became at risk of l e~k o s t a s i s .~~~~~ After this consolidation course, patients were scheduled to receive three "2 + 5" DNR and Ara C courses followed by reinduction courses and prolonged maintenance with 6 mercaptopurine and methotrexate during 2% years (Table 1) . The rationale for the use of prolonged maintenance chemotherapy came from studies suggesting that this form of therapy could perhaps prolong remissions in APL.2 BMT was offered to patients with an HLA identical sibling. During treatment with ATRA, no systematic DIC prophylaxis (especially with heparin) was administered, and platelet transfusions were generally administered only if platelet counts were less than 30 x 109/L. All patients received cold cream, eye drops, and nasal drops to alleviate the dryness of skin and mucosae usually seen with ATRA.
Analysis of event-free survival (taking into account failure to achieve CR, relapse, and death in CR as "events") and diseasefree interval (censoring patients who died in CR) of the patient population was made in August 1992, 18 months after the last patient's inclusion. These results were compared with event-free survival and disease-free interval of a historical APL population included in our previous APL 84 trial consisting of chemotherapy alone (induction with Amsacrine or zorubicine and Ara C, followed by similar consolidation and maintenance as in the current pilot study).* In this APL 84 trial, 10 of 39 patients presented with hyperkeukocytosis. Although their outcome (8 of 10 obtained CR, and 2 had prolonged CR) did not significantly differ from that of the other patients, they were excluded from comparison with the present pilot study. This was because APL patients presenting with hyperleukocytosis are considered to have poorer p r o g n o s i~,~,~ and no patients with initial hyperleukocytosis had been included in the present study.
RESULTS
Initial characteristics of the 26patients. Initial characteristics of the 26 patients are summarized in Table 2 . Median age was 46 (range 25 to 63). There were 15 females and 11 males. Median leukocyte count was 1.4 X 109/L (range 0.4 to 4.2 x 109/L). A significant hemostatic disorder was present in 19 patients, of whom 15 had bleeding symptoms. Morphologically, all patients had "classical" hypergranular APL, and no patient had the microgranular variant. Of the 25 patients studied cytogenetically, 24 had a t( 15;17) translocation, and the remaining patient (no. 26) had isolated trisomy 10.
Results of induction treatment. Twenty-five patients (96%) achieved CR. Fourteen of them obtained CR with ATRA alone, after 35 to 80 days. In the other 11 patients, chemotherapy with the "4 + 7" course was started after 2 to 30 days of treatment with ATRA. In eight patients, chemotherapy was added to ATRA because of a rapid increase in leukocyte count, above 6 x 109/L by day 5 or 10 x 109/L by day 10, or 15 x 109/L by day 15, as scheduled in the protocol. In another patient (no. 23), the increase in leukocytes was slower. However, on day 21 the leukocyte count was 28 x 109/L and signs of pulmonary leukostasis started to develop, leading to rapid onset of the "4 + 7" course. In the two remaining cases, this chemotherapy course was administered after 18 and 30 days of ATRA, because of resistance to ATRA (patient no. 21) and development of organomegaly (patient no. 22), respectively.
In patient no. 21, no signs of differentiation of abnormal promyelocytes were present in vivo, no improvement of platelet counts and coagulation parameters occurred, and the bone marrow aspirate on day 15 was still massively infiltrated by abnormal promyelocytes, leading to the onset of chemotherapy on day 16. In patient no. 22, organomegaly (cervical lymphadenopathy, hepatomegaly, labial and gum hypertrophy) accompanied by fever of undetermined origin started to develop on day 10, in association to a moderate increase in leukocytes from 1.3 to 9.3 x 109/L. On day 30, because organomegaly was increasing, and although leukocyte counts (which had peaked to 16 x 109/L) started to diminish and in vivo differentiation of abnormal promyelocytes was present, chemotherapy was started. Rapid disap- pearance of organomegaly occurred and CR was obtained.
In patients nos. 21 and 22 (contrary to the other nine patients in whom early onset of chemotherapy was necessary), ATRA was stopped when chemotherapy was started. Both patients had a t(15;17) translocation. The only patient who did not achieve CR (no. 20) had a rapid increase in leukocytes, leading to the addition of chemotherapy on day 5. However, this patient died the next day from an intracerebral hematoma. At diagnosis, this patient had cutaneomucous bleeding but with normal fundus oculi. There was a severe hemostatic disorder with fibrinogen = 0.5 g/L, FSP = 80 pg/mL, and platelet count = 18 x 109/L.
Apart from hyperleukocytosis, and from organomegaly in one patient, side effects were generally mild, limited to dryness of the skin and mucosae. In three patients (including the patient in whom organomegaly developed) fever, apparently not related to infection, occurred after 10, 16, and 24 days of treatment with ATRA, respectively. In only one of the three patients (no. 22), this was associated to progressive increase in leukocyte counts. Apyrexia was obtained after discontinuation of ATRA in two cases, despite continued administration of the drug in the remaining patient. In another patient, fever associated to moderate pleural effusion and myocardial failure was observed. All signs disappeared after a few days, although the drug was continued. It remained uncertain whether this complication was caused by ATRA or was secondary to an infection, especially viral, in this patient.
The hemostatic disorder rapidly improved except in two patients (patient no. 20, who died from central nervous system [CNS] bleeding and patient no. 22 who had resistance to ATRA). Of the 14 patients who achieved CR with ATRA alone, only 4 required platelet transfusions and only 5 required antibiotics for less than 1 week.
Correlation between in vivo and in vitro response to ATRA. All the 11 samples tested in vitro showed a very good response to ATRA lo-6 mol/L after 6 days of culture (differentiation of 92.8% ? 4% of abnormal promyelocytes). Those 11 patients also had in vivo differentiation with ATRA. The only patient with no in vivo response to ATRA was unfortunately not tested in vitro.
ATRA induced an increase in the viable cell count in 5 cases. Hyperleukocytosis was clinically observed in 4 of these patients. Likewise, no in vitro stimulation of the viable cell count was observed in the other 6 patients, 5 of whom had in vivo stable leukocyte counts. Thus, 2 out of the 11 samples studied failed to predict in vivo proliferation. However, one sample was taken 8 days after the onset of ATRA and the other was delivered 5 days after sampling. It 1 1 1 1 1 1 , 1 , , 1 1 , 1 , , 1 , , 
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is highly probable that cell kinetics and viability may be modified in these conditions. Overall, in vitro assays of APL cells in the presence of ATRA gave a very good correlation between in vitro and in vivo differentiation and proliferation with ATRA.
Of the 25 patients who achieved CR, 4 patients did not receive the intensive "4 + 7" DNR-Ara C regimen, because of refusal (2 cases) or medical decision (2 cases). However, they received the following three "2 + 5" DNR-Ara C courses and maintenance therapy scheduled on Table 1 . The remaining 21 patients received the "4 + 7" regimen. This regimen was started in 11 cases before CR achievement, as seen above, and after CR achievement in the other 10 cases, 30 to 100 days (median 80) after the onset of ATRA. This course was not associated to any mortality. Median time to neutrophils > 0.5 x 109/L was 20 days (range 0 to 32) and median time to platelets > 50 x 109/L was 20 days (range 8 to 40). When this course was administered in patients who were receiving ATRA, it was not associated to reappearance of the hemostatic disorder, except in one patient.
Three of the 21 patients who received the "4 + 7"
regimen were allografted after recovery from aplasia, from an HLA-identical sibling. Another patient, scheduled to receive an autograft 6 months after achieving CR, died during the conditioning regimen. The cause of death remained unknown. The remaining 17 patients received (and are still receiving) the scheduled maintenance chemotherapy (Table 1) . Three patients relapsed, after 8, 11, and 15 months, including one of the allografted patients (after 8 months) and two patients who had received the full scheduled consolidation therapy. Two patients died in CR, including the patient who died before an autograft, and a patient who died after 17 months, from septic shock during the phase of aplasia following a reinduction course. Twenty patients remained in CR after 18+ to 34+ (median 21 months). Actuarial disease-free interval was 87% after 18 months with no subsequent relapse (Fig 1) . Actuarial event-free survival was 77% after 18 months, with no subsequent event so far (Fig 1) .
The present results were compared with those of 29 APL patients included in our previous APL 84 trials who had leukocytes < 10 x 109/L at diagnosis. Median age of this control population was 47 (range 1 to 64), and median leukocyte count 1.5 x 109/L (range 0.3 to 7.8). Only one patient had the microgranular APL variant. Twenty-two patients (76%) achieved CR. Actuarial disease-free interval (Fig 1A) was 59% after 18 months, and actuarial event-free survival (Fig 1B) 48% after 18 months. The difference between the present pilot study and the control APL 84 trial population was significant for event-free survival (P = .006) and for disease-free interval (P = .02), but not for CR achievement (P = .OS).
Evolution in patients who achieved CR.

DISCUSSION
Our results confirm the high CR rate obtained with ATRA in newly diagnosed APL by other groups: 15 CR in 16 patients'l and 41 CR in 44 patients. 13 We also found a high CR rate in APL treated with ATRA in first relapse (19 CR in 20 patients).15 As in our experience in first relapse APL and in the experience of other groups, a rapid improvement of coagulation parameters was almost universally observed, and CR was achieved without any phase of aplasia.11-15 Although 14 of our patients achieved CR with ATRA alone, 11 received chemotherapy in addition to ATRA before they entered CR. The reason for adding chemotherapy to ATRA was generally a rapid increase in leukocyte counts. In our previous experience of treatment of newly diagnosed APLwith ATRA in elderly patients with contraindication to chemotherapy, an early and rapid increase in leukocyte counts occurred in about 30% of the patients. Hyperleukocytosis frequently led to signs of leukostasis, including diffuse lung infiltrates, renal failure, and severe CNS impairment, and to a fatal outcome. 16 
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was constant in patients with initial hyperleukocytosis, but also occurred in initially leukopenic patients (who represent the majority of APL). In this early experience, all patients who subsequently developed this syndrome had leukocytes > 6 X 109/L by day 5, or > 10 x 109/L by day 10, or > 15 x 109/L by day 15, whereas patients with leukocytes below these thresholds did not develop l e u k o~t a s i s .~~J~ Although Huang et all1 and Chen et all3 did not report cases of major hyperleukocytosis in their patients, Frankel et all8 found this side effect in 9 of their 35 patients with newly diagnosed APL treated with ATRA. In those patients, hyperleukocytosis was often associated to fever, edema, pulmonary failure, and sometimes to pleural or pericardial effusion and cardiac failure, constituting the "retinoic acid syndrome" (RA syndrome). Three of the nine patients with this syndrome died. Leukaphereses, performed in five patients, rapidly lowered the leukocyte counts in only two patients. Likewise, when leukocytes rapidly increased, low-dose chemotherapy (including hydroxyurea or low-dose Ara C) proved insufficient in rapidly lowering the leukocyte count in our experience.17 Thus, a more intensive approach for reversing hyperleukocytosis, like the "4 + 7" regimen we have used in this report, seems necessary. Another approach in patients with the RA syndrome may be the use of dexamethasone which, in five patients with the RA syndrome, led to reversal of symptoms without any change of leukocyte countsls (and W. Bollag, personal communication, October 1991). This effect of steroids suggests a possible role for the release of cytokines in the pathogenesis of the RA syndrome.
Apart from hyperleukocytosis, side effects of ATRA were generally mild. Of note, however, was the occurrence of organomegaly in one patient. This side effect had not previously been reported with ATRA, to our knowledge. In this patient, because gum and labial hypertrophy became prominent, ATRA was stopped and the "4 + 7" DNR + Ara C regimen started. In this patient and two other patients, fever without any evidence of infection, reminiscent of the RA syndrome,ls was observed. In another patient, myocardial failure with pleural effusion and fever could also have been attributed to the RA syndrome, although infection could not be ruled out.
The aim of the "4 + 7" DNR + Ara C regimen used in this pilot study was twofold: provide a rapid reduction in leukocyte counts in patients with a rapid increase in leukocytes, and achieve more prolonged remissions by further reducing the leukemic burden in all cases. This regimen was not associated with any mortality, and the duration of aplasia was generally moderate. Of note was that, when this regimen was added to ATRA because of hyperleukocytosis, no recurrence of the hemostatic disorder was observed except in one case.
In the patients for whom in vitro studies could be performed, we found an excellent correlation between in vitro differentiation/proliferation and the clinical response to ATRA. These data suggest that in vitro behavior of APL cells in the presence of ATRA mimic in vivo response and confirm the validity of the in vitro studies for the assessment of clinical response and/or side effects of RA.
A major finding, in this pilot study, was the low incidence of relapses. Only 3 of the 25 patients relapsed. Actuarial disease-free interval was 87% after 18 months. Although follow-up remained relatively short in many patients, this low incidence of relapses may be significant because, in previous reports of chemotherapy in APL, about two thirds of the relapses occurred during the first 18 months after CR a~hievement.~-~ In our recent APL 84 trial (with chemotherapy alone) in APL,s disease-free interval was 59% after 18 months, after excluding patients who presented with hyperleukocytosis, who may be at higher risk of early death or r e l a p~e .~,~ Furthermore, because of the high CR rate obtained in the present study, actuarial event-free survival (which takes into account failure to achieve CR, relapse, and death in CR) was as high as 77% after 18 months. In previous reports on APL treated with chemotherapy, actuarial event-free survival after 1 year was only 40% to 50%1-7 and it was 48% in our APL 84 trial (after excluding patients who presented with hyperleukocytosis). Differences between the present study with ATRA followed by chemotherapy and the APL 84 trial were significant for disease-free interval and event-free survival. It has been stressed that comparison with a historical population can be misleading and should not be overinterpreted. In addition, because follow-up in the present study is relatively limited, one could argue that ATRA followed by intensive chemotherapy may only delay relapses. Still, our results suggest that this approach may be superior to chemotherapy alone in APL by slightly increasing the CR rate, but perhaps more importantly by reducing the incidence of relapses. The question is currently addressed in a multicenter European protocol randomizing ATRA followed by intensive chemotherapy and intensive chemotherapy alone in newly diagnosed APL. 
